We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trough Bronchoprotection Conferred by Levosalbutamol and Racemic Salbutamol (NAI009)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00831376
First Posted: January 28, 2009
Last Update Posted: June 12, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Brian J Lipworth, University of Dundee
  Purpose
The objective of this study is to compare the relative bronchoprotection (at trough) conferred by 2-week chronic dosing with levosalbutamol and racemic salbutamol in mild to moderate asthmatics. Patients will be preselected into two groups on the basis of their beta-2 adrenoreceptor polymorphisms. The investigators will evaluate if this has a differential effect on the bronchoprotection conferred by both formulations of salbutamol, as evidenced by a rebound in airway hyper-responsiveness, in order to determine whether any effect can be explained by the S enantiomer in the racemic formulation.

Condition Intervention Phase
Asthma Drug: levosalbutamol Drug: racemic salbutamol Drug: placebo Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Proof of Concept Study to Evaluate the Trough Bronchoprotection Conferred by Chronic Dosing With Levosalbutamol and Racemic Salbutamol in Persistent Asthmatics

Resource links provided by NLM:


Further study details as provided by Brian J Lipworth, University of Dundee:

Primary Outcome Measures:
  • methacholine challenge [ Time Frame: before and after 2 week study period ]

Secondary Outcome Measures:
  • spirometry [ Time Frame: before and after 2 week study period ]
  • nitric oxide levels [ Time Frame: before and after 2 week study period ]
  • symptom scores [ Time Frame: before and after 2 week study period ]
  • Bmax and Emax [ Time Frame: before and after 2 week study period ]

Enrollment: 30
Study Start Date: January 2009
Study Completion Date: April 2012
Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: levosalbutamol
Patients will be asked to take two puffs four times a day for 2 weeks
Drug: levosalbutamol
Patients will be asked to take two puffs four times a day for 2 weeks
Active Comparator: 2: racemic salbutamol
Patients will be asked to take two puffs four times a day for 2 weeks
Drug: racemic salbutamol
Patients will be asked to take two puffs four times a day for 2 weeks
Other Name: Ventolin
Placebo Comparator: 3: Placebo
Patients will be asked to take two puffs four times a day for 2 weeks
Drug: placebo
Patients will be asked to take two puffs four times a day for 2 weeks

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Mild to moderate stable asthmatics on ≤ 2000μg BDP or equivalent, who are methacholine responsive PC20< 4 mg/ml
  2. >1dd change in methacholine PC20 after the administration of racemic Salbutamol.
  3. Male or female 18-65
  4. Informed Consent
  5. Ability to comply with the requirements of the protocol

Exclusion Criteria:

  1. Severe asthmatics as defined by an FEV1≤ 60% or PEF variability > 30% or with continual daytime or nocturnal symptoms.
  2. The use of oral corticosteroids within the last 3 months.
  3. Recent respiratory tract infection (2 months).
  4. Significant concomitant respiratory disease such as COPD, CF, ABPA, bronchiectasis and active pulmonary tuberculosis.
  5. Any other clinically significant medical condition such as unstable angina, acute myocardial infarction in the preceding 3 months, recent TIA/ CVA, that may endanger the health or safety of the participant, or jeopardise the protocol.
  6. Any significant abnormal laboratory result as deemed by the investigators
  7. Pregnancy, planned pregnancy or lactation
  8. Known or suspected contra-indication to any of the IMP's
  9. Concomitant use of medicines (prescribed, over the counter or herbal) that may interfere with the trial.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00831376


Locations
United Kingdom
Asthma and Allergy Research Group
Dundee, Angus, United Kingdom, DD1 9SY
Sponsors and Collaborators
University of Dundee
Investigators
Principal Investigator: Karine L Clearie, MBBS, MRCP Asthma and Allergy Research Group
Study Director: Brian J Lipworth, MBchB Asthma and Allergy Research Group
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Brian J Lipworth, Professor, University of Dundee
ClinicalTrials.gov Identifier: NCT00831376     History of Changes
Other Study ID Numbers: NAI009
First Submitted: January 27, 2009
First Posted: January 28, 2009
Last Update Posted: June 12, 2012
Last Verified: June 2012

Keywords provided by Brian J Lipworth, University of Dundee:
Asthma
Genotype
Beta2adrenoreceptor
Levosalbutamol

Additional relevant MeSH terms:
Albuterol
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Tocolytic Agents
Reproductive Control Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action